Phase 3 Readout

TGTX: Phase 3 Topline: Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )

Name: Phase 3 Topline: Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )
Start: 2027-01-21
End: 2027-01-21

January 21, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 21, 2027
Company: TG THERAPEUTICS, INC. (TGTX)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )

January 21, 2027

TGTX overview →

Company: TG THERAPEUTICS, INC. (TGTX)
Indication: Relapsing Multiple Sclerosis